Claims for Patent: 10,001,469

Summary for Patent: 10,001,469

Title:	Use of GPR83 to identify pruritus-related substances
Abstract:	The present invention provides a peptide having antagonist activity against SP, pain control activity, anti-inflammation activity, and anti-pruritic activity. The present invention further provides a method for searching for a therapeutic agent for pain, a therapeutic agent for inflammation, and a therapeutic agent for pruritus using G protein coupled receptor (GPR) 83, which is an HK-1 specific receptor.
Inventor(s):	Nishimori; Toshikazu (Miyazaki, JP), Nakayama; Rumi (Miyazaki, JP)
Assignee:	University of Miyazaki (Miyazaki, JP)
Application Number:	14/823,378
Patent Claims:	1. A method for evaluating, in vivo, a test substance in a non-human animal, comprising: administering a GPR83 inhibitor to a first non-human animal and a second non-human animal, wherein the GPR83 inhibitor is selected from the group consisting of a polypeptide, an antibody, an antisense inhibitor, and an siRNA; administering a first test substance to the first non-human animal; administering a control substance to the second non-human animal; comparing itching behavior in the first non-human animal and itching behavior in the second non-human animal; and evaluating whether or not the first test substance is a pruritus-related substance based on an increase or decrease in itching behavior. 2. The method of claim 1, further comprising: determining that the first test substance is a pruritus inhibiting substance if the itching behavior in the first non-human animal is suppressed. 3. A method for evaluating, in vivo, a test substance in a non-human animal, comprising: administering a GPR83 inhibitor to a first non-human animal wherein the GPR83 inhibitor is selected from the group consisting of a polypeptide, an antibody, an antisense inhibitor, and an siRNA; administering a test substance to the first non-human animal; administering the test substance to a second non-human animal in which the GPR83 function is not inhibited; administering a compound that induces itching to the first non-human animal and the second non-human animal; and comparing itching behavior in the first non-human animal and itching behavior in the second non-human animal; wherein a decrease in the itching behavior in the first non-human animal compared to the second non-human animal indicates that the test substance is an agonist of GPR83, and wherein an increase in the itching behavior in the first non-human animal compared to the second non-human animal indicates that the test substance is an antagonist of GPR83. 4. The method of claim 3, wherein the compound that induces itching is selected from the group consisting of histamine and serotonin.

Details for Patent 10,001,469

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	03/13/1924		2030-08-27